deltatrials
Recruiting OBSERVATIONAL NCT06157060

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA

Sponsor: Zhujiang Hospital

Conditions Hepatocellular Carcinoma Resectable
Interventions circulating tumor DNA
Updated 4 times since 2024 Last updated: Mar 26, 2024 Started: Nov 20, 2023 Primary completion: Nov 20, 2023 Completion: Dec 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Hepatocellular Carcinoma Resectable, this trial is actively recruiting participants. The trial is conducted by Zhujiang Hospital and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting

  3. Apr 2024 — Jul 2024 [monthly]

    Recruiting

  4. Jan 2024 — Apr 2024 [monthly]

    Recruiting

    First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Zhujiang Hospital
Data source: Zhujiang Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations